Windtree Therapeutics, Inc. (NASDAQ:WINT – Get Rating) – Equities research analysts at Oppenheimer issued their FY2026 earnings per share estimates for shares of Windtree Therapeutics in a research note issued on Wednesday, April 20th. Oppenheimer analyst L. Gershell forecasts that the company will post earnings of ($0.29) per share for the year.
WINT opened at $0.81 on Friday. Windtree Therapeutics has a fifty-two week low of $0.80 and a fifty-two week high of $3.40. The company has a debt-to-equity ratio of 0.36, a quick ratio of 4.77 and a current ratio of 4.77. The company has a market capitalization of $23.05 million, a P/E ratio of -0.30 and a beta of 0.06. The stock has a fifty day moving average of $1.04 and a 200-day moving average of $1.41.
A number of hedge funds have recently bought and sold shares of the stock. Renaissance Technologies LLC raised its stake in Windtree Therapeutics by 15.0% in the fourth quarter. Renaissance Technologies LLC now owns 215,500 shares of the company’s stock valued at $346,000 after purchasing an additional 28,100 shares in the last quarter. Geode Capital Management LLC raised its stake in Windtree Therapeutics by 129.8% in the third quarter. Geode Capital Management LLC now owns 158,747 shares of the company’s stock valued at $327,000 after purchasing an additional 89,665 shares in the last quarter. Skandinaviska Enskilda Banken AB publ raised its stake in Windtree Therapeutics by 15.7% in the third quarter. Skandinaviska Enskilda Banken AB publ now owns 110,500 shares of the company’s stock valued at $228,000 after purchasing an additional 15,000 shares in the last quarter. Finally, Citadel Advisors LLC acquired a new position in Windtree Therapeutics in the fourth quarter valued at about $66,000. 10.62% of the stock is owned by institutional investors and hedge funds.
Windtree Therapeutics Company Profile (Get Rating)
Windtree Therapeutics, Inc, a clinical-stage biotechnology and medical device company, focuses on the development of therapeutics for the treatment of acute pulmonary and cardiovascular diseases. Its lead development programs include istaroxime, which is in Phase 2b clinical trial for the treatment of acute decompensated heart failure, as well as in Phase 2a clinical trial for the treatment of early cardiogenic shock; AEROSURF, an aerosolized KL4 surfactant, which is in Phase 2b clinical trial to treat respiratory distress syndrome (RDS) in premature infants; lyophilized KL4 surfactant for the treatment of lung injury resulting from COVID-19; and Rostafuroxin that is in Phase 2b clinical trial for the treatment of genetically associated hypertension.
- Get a free copy of the StockNews.com research report on Windtree Therapeutics (WINT)
- 3 Resilient Stocks to Buy for Retirement
- MarketBeat: Week in Review 4/18 – 4/22
- Tractor Supply Company Reaps What It Sows
- Snap (NYSE: SNAP) Gives Investors A Mixed Bag
- Should You Buy Carvana or AutoNation or Pass on Both?
Receive News & Ratings for Windtree Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Windtree Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.